SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-150866
Filing Date
2021-05-05
Accepted
2021-05-05 08:05:54
Documents
14
Period of Report
2021-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d171599d8k.htm   iXBRL 8-K 26114
2 EX-99.1 d171599dex991.htm EX-99.1 68896
6 GRAPHIC g171599g0505023428476.jpg GRAPHIC 4601
  Complete submission text file 0001193125-21-150866.txt   238728

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvs-20210505.xsd EX-101.SCH 3092
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20210505_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20210505_pre.xml EX-101.PRE 11422
7 EXTRACTED XBRL INSTANCE DOCUMENT d171599d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 21891247
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences